Study Institution | Number of patients | Total dose of XRT (Gy) | Chemo-therapy (mg/m2) | Median OS (months) | 1(2,4,5)-year-OS-rate (%) | Rate local recurrence (%) | Rate of resectability (%) | Rate of clear resections |
---|---|---|---|---|---|---|---|---|
Hoffman et al. 1998[39, 40] multi-centric | 53 | 50.4 | 5-FU/MMC | 9.7 all pts 15.7 res | 2y: 27 res | 24/53 (26 %) 3/24 (13%) res | 24/53 (45%) | n.a |
Snady et al. 2000 [29]Mount Sinai | 159 68* (20 res§) 91 adj | 54 + 14 Gy | 5-FU/cDDP/Streptozotocin | 23.6* (32 res) 14.0 | 1 y: 86*(89)vs.64 2y: 58*(60) vs.32 3y: 27*(40)vs.17 | n.a. | 20/68 (29%) - | 95% neo 84% adj |
Breslin et al. 2001 [20] MDACC | 132 | 45 or 50.4 Gy or 10 × 3 Gy ± IORT | 5-FU, or Tax or Gem | 21 | 1y: 75 2y: 40 5y: 23 | 8/132 (6%) | - | 88% |
Sasson AR et al.2003 [28]FCCC | 116 61 neo 55 adj | 50.4 | 5-FU/MMC or Gem | all 18 neo 23 adj 16 | n.a. | n.a. | - | 39% n.a. n.a. |
White et al. 2005 [21]Duke | 193 i.p.r.:102 i.l.f.: 91 | 45 + 5.4 Gy | 5-FU or Gem | 23 39 i.p.r. 20 i.l.f. | 3y: 37 res 5y: 27 res | n.a. | 70/193 (36%) 54/102 (53%) 16/91 (18%) | 73% n.a. n.a. |